A senior scientist at the Princess Margaret Cancer Centre, Dr. Linda Penn holds a Tier-1
Canada Research Chair in Molecular Oncology. Her research has focused on the
molecular and cellular properties of the family of Myc genes that are directly implicated
in many types of cancer and which, thanks to her work and others, has recently become
a tractable target for new therapies. She is recognized internationally as a leader in
the understanding of oncogene function and has driven the identification of Myc
binding partners and post transactional modifications. Dr. Penn has also made multiple
discoveries in the role of statin drugs in interfering with tumour growth through
induction of cell death. She has been a board member of the Ontario division of
the Canadian Cancer Society and served on many peer review and advisory committees for cancer research. She is a former Terry Fox New Investigator and has been a member of two previously funded New Frontiers Program Project Grants.